Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model

Cancer Biology and Therapy

Volumn 8, Issue 20, 2009, Pages 1924-1933

  Ningaraj, Nagendra S ^a   Sankpal, Umesh T ^a   Khaitan, Divya ^a   Meister, Edward A ^b   Vats, Tribhawan S ^c  

^a MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b Clinical Research and Medical Education Department   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Blood brain barrier; Drug delivery; Glioma; KCa channels; NS1619; Temozolomide; Trastuzumab

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; CALCIUM ACTIVATED POTASSIUM CHANNEL; TEMOZOLOMIDE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; DACARBAZINE; DRUG DERIVATIVE; KCNMA1 PROTEIN, HUMAN; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL ALPHA SUBUNIT; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CANCER SURVIVAL; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; FEMALE; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOCALIZATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAT; XENOGRAFT; ANIMAL; APOPTOSIS; BRAIN; BRAIN TUMOR; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; FLOW CYTOMETRY; GENETICS; IMMUNOBLOTTING; METABOLISM; METHODOLOGY; NUDE MOUSE; NUDE RAT; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZIMIDAZOLES; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; DRUG DELIVERY SYSTEMS; FEMALE; FLOW CYTOMETRY; GLIOMA; HUMANS; IMMUNOBLOTTING; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNEL ALPHA SUBUNITS; MICE; MICE, NUDE; RATS; RATS, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73549104486     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.20.9490     Document Type: Article

References (55)

1. Ningaraj NS. Drug delivery to brain tumours: challenges and progress. Expert Opin Drug Deliv 2006; 3:499-509.
2. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 2008; 14:2900-8.
3. Ningaraj NS, Rao M, Hashizume K, Asotra K, Black KL. Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharmacol Exp Ther 2002; 301:838-51.
4. Ningaraj NS, Rao M, Black KL. Calcium-dependent potassium channels as a target protein for modulation of the blood-brain tumor barrier. Drug News Perspect 2003; 16:291-8.
5. Black KL, Ningaraj NS. Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. Cancer Control 2004; 11:165-73.
6. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3- methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47:5846-52.
7. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997; 23:35-61.
8. Tsang LL, Quarterman CP, Gescher A, Slack JA. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother Pharmacol 1991; 27:342-6.
9. Friedman HS, Dolan ME, Pegg AE, Marcelli S, Keir S, Catino JJ, et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 1995; 55:2853-7.
10. Plowman J, Waud WR, Koutsoukos AD, Rubinstein LV, Moore TD, Grever MR. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 1994; 54:3793-9.
11. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999; 17:2762-71.
12. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000; 6:2585-97.
13. Mutter N, Stupp R. Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther 2006; 6:1187-204.
14. Kanzawa T, Bedwell J, Kondo Y, Kondo S, Germano IM. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 2003; 99:1047-52.
15. 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999; 5:309-17.
16. 14C]-labeled tracers. Methods Mol Med 2003; 177-90.
17. Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006; 24:1253-65.
18. Potti A, Forseen SE, Koka VK, Pervez H, Koch M, Fraiman G, et al. Determination of HER-2/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors. Cancer Invest 2004; 22:537-44.
19. Blajeski AL, Phan VA, Kottke TJ, Kaufmann SH. G(1) and G(2) cell cycle arrest following microtubule depolymerization in human breast cancer cells. J Clin Invest 2002; 110:91-9.
20. Pegram MD, Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 1999; 26:89-95.
21. Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM. Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 2002; 8:2725-34.
22. Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001; 61:1957-63.
23. Sontheimer H. Ion channels and amino acid transporters support the growth and invasion of primary brain tumors. Mol Neurobiol 2004; 29:61-71.
24. Weaver AK, Liu X, Sontheimer H. Role for calcium-activated potassium channels (BK) in growth control of human malignant glioma cells. J Neurosci Res 2004; 78:224-34.
25. Pardridge WM. Drug targeting, drug discovery and brain drug development. Brain drug targeting: The future of brain drug development. Cambridge: Cambridge University Press 2001; 1-13.
26. Heimberger AB, Archer GE, McLendon RE, Hulette C, Friedman AH, Friedman HS, et al. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin Cancer Res 2000; 6:4148-53.
27. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96.
28. Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 2003; 21:2305-11.
29. Darkes MJM, Plosker GL, Jarvis B. Temozolomide A Review of its Use in the Treatment of Malignant Gliomas, Malignant Melanoma and Other Advanced Cancers. Am J Cancer 2002; 1:55-80.
30. Sibghat U, Day RS, 3rd. Incision at O6-methylguanine:thymine mispairs in DNA by extracts of human cells. Biochemistry 1992; 31:7998-8008.
31. 6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro Oncol 2004; 6:28-32.
32. 6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 1995; 51:167-223.
33. Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res 1999; 5:2908-17.
34. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 2002; 3:53-7.
35. Black KL, Hoff JT, McGillicuddy JE, Gebarski SS. Increased leukotriene C4 and vasogenic edema surrounding brain tumors in humans. Ann Neurol 1986; 19:592-5.
36. Inamura T, Black KL. Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J Cereb Blood Flow Metab 1994; 14:862-70.
37. Sugita M, Black KL. Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability into brain tumors. Cancer Res 1998; 58:914-20.
38. Ningaraj NS, Rao MK, Black KL. Adenosine 5'-triphosphate-sensitive potassium channel-mediated blood-brain tumor barrier permeability increase in a rat brain tumor model. Cancer Res 2003; 63:8899-911.
39. Agarwala SS, Reyderman L, Statkevich P. Pharmacokinetic study of temozolomide penetration into CSF in a patient with dural melanoma. Annals of Oncology 1998; 9:139.
40. Patel M, McCully C, Godwin K, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 2003; 61:203-7.
41. Reyderman L, Statkevich P, Thonoor CM, Patrick J, Batra VK, Wirth M. Disposition and pharmacokinetics of temozolomide in rat. Xenobiotica 2004; 34:487-500.
42. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000; 5:144-51.
43. Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res 2001; 61:5491-8.
44. Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004; 10:3728-36.
45. Patel M, McCully C, Godwin K, Balis F. Plasma and cerebrospinal fluid pharmacokinetics of temozolomide. Proc Natl Acad Sci USA 1995; 14:461.
46. Zhou Q, Guo P, Kruh GD, Vicini P, Wang X, Gallo JM. Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Clin Cancer Res 2007; 13:4271-9.
47. Meikle SR, Matthews JC, Brock CS, Wells P, Harte RJ, Cunningham VJ, et al. Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. Cancer Chemother Pharmacol 1998; 42:183-93.
48. Fuller GN, Bigner SH. Amplified cellular oncogenes in neoplasms of the human central nervous system. Mutat Res 1992; 276:299-306.
49. Ca) US patent 7211561 2007.
50. Rao M, Ningaraj N. Activation of Calcium-dependent potassium channels elicits selective glioma cell death. AACR-NCI-EORTC 2001.
51. Han X, Xi L, Wang H, Huang X, Ma X, Han Z, et al. The potassium ion channel opener NS1619 inhibits proliferation and induces apoptosis in A2780 ovarian cancer cells. Biochem Biophys Res Commun 2008; 375:205-9.
52. Forseen SE, Potti A, Koka V, Koch M, Fraiman G, Levitt R. Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors. Anticancer Res 2002; 22:1599-602.
53. Kottke TJ, Blajeski AL, Martins LM, Mesner PW Jr, Davidson NE, Earnshaw WC, et al. Comparison of paclitaxel-, 5-fluoro-2'-deoxyuridine-, and epidermal growth factor (EGF)-induced apoptosis. Evidence for EGF-induced anoikis. J Biol Chem 1999; 274:15927-36.
54. Ohno K, Pettigrew KD, Rapoport SI. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol 1978; 235:299-307.
55. Bland JM. An introduction to medical statistics. London: Oxford University Press 2003.